Product Information

AMITIZA 24 MCG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $5.9498 per EA under NDC 64764024060. Its NADAC has been published 638 times since Nov 28, 2013.

FDA first approved this application on Jan 31, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the lubiprostone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

AMITIZA 24 MCG CAPSULE

lubiprostone
$5.9498per EA
High Outlier

Strength

24 ug/1

NDC

64764024060

Classification

Brand

Dosage Form

CAPSULE, GELATIN COATED

Route

ORAL

Effective Date

2/19/2025

Active Ingredients

LUBIPROSTONE

Approval Type

New Drug (NDA)

FDA Application

NDA021908

FDA Approved

1/31/2006

TE Code

AB

On Market Since

1/31/2006

Pharmacological Classes

Chloride Channel Activator
Chloride Channel Activators

Price Statistics

The NADAC for AMITIZA 24 MCG CAPSULE has been published 638 times since Nov 28, 2013, and over the history we have for it it has risen 33.6%. The table below summarizes its recorded NADAC range and movement.

Current price$5.9498 per EA
All-time high$5.9498 (Feb 11, 2026)
All-time low$4.4519 (Nov 28, 2013)
52-week high$5.9498
52-week low$5.9498
Median price$5.9330
Average price$5.6756
Largest weekly change+9.0% (Apr 9, 2014)
Weeks tracked638
Tracking sinceNov 28, 2013

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

0.0%

3Y

+0.3%

5Y

+0.2%

All

+33.6%

Last surveyed Feb 11, 2026 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 90% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Related Drugs

Same classification

No related drugs found.

Frequently asked questions

What is the NADAC price of AMITIZA 24 MCG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for AMITIZA 24 MCG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $5.9498 per EA (NDC 64764024060), effective Feb 11, 2026.

How has the price of AMITIZA 24 MCG CAPSULE changed over time?

Over the history we have for it, the NADAC for AMITIZA 24 MCG CAPSULE has risen 33.6%. It has been tracked across 638 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for AMITIZA 24 MCG CAPSULE?

Since Nov 28, 2013, the NADAC for AMITIZA 24 MCG CAPSULE has ranged from a low of $4.4519 (Nov 28, 2013) to a high of $5.9498 (Feb 11, 2026), with a median of $5.9330 per EA.

Are there cheaper alternatives to AMITIZA 24 MCG CAPSULE?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LUBIPROSTONE 24 MCG CAPSULE, is $0.6239 per EA — about 90% below AMITIZA 24 MCG CAPSULE.

Who manufactures AMITIZA 24 MCG CAPSULE?

AMITIZA 24 MCG CAPSULE (NDC 64764024060) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.